

CONTROVERSIES IN BREAST CANCER

Date and time: Tuesday 3rd May 2022, 11:30-12:30 CEST

Location: Cologne Hall, Hub27, Berlin

An expert panel of speakers will:

- Explore the role and value of different efficacy endpoints in the early breast cancer setting
- Define HER2-low and its importance in the evolving BC treatment landscape
- Seek to understand CDK4/6i and the significance of treatment sequencing



11:30-11:45 CEST

How important is OS data for treatment decisions?

Prof. Sibylle Loibl (Chair), German Breast Group, Germany



11:45-12:00 CEST

What do we know About HER2-Low Breast Cancer?

Dr. Paolo Tarantino, European Institute of Oncology, Italy



12:00-12:15 CEST

Treatment beyond CDK4/6i - what comes next?

Prof. Rebecca Dent, National University of Singapore, Singapore



12:15-12:30 CEST

Q&A / panel discussion

All Speakers